Skip to content
CNS Clinical Research

Orlando, Florida

CNS clinical trials in Orlando, FL

57 CNS studies are recruiting participants at sites in Orlando as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Orlando at a glance

  • 57 studies are recruiting at a site in Orlando.
  • By phase: Phase 1 (2), Phase 2 (17), Phase 3 (26), Phase 4 (4), No phase (4), Observational (4). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (51), university, hospital or other (6).
  • By research area: Depression (21), Parkinson's Disease (10), Migraine (7), Multiple Sclerosis (6), Schizophrenia (5), ADHD (4), Epilepsy (3), Bipolar Disorder (1).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Orlando

Basic details from each study's public record (the 30 most recently updated of 57). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    CNS Healthcare of Orlando
    Registry record
    NCT07226661 · updated
  2. A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Seaport Therapeutics
    Study site
    Seaport Investigator Site
    Registry record
    NCT07065240 · updated
  3. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Clinical Neuroscience Solutions, LLC (Orlando)
    Registry record
    NCT07592689 · updated
  4. Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics

    • No phase
    • Ages 60 and older
    • All sexes
    Sponsor
    AdventHealth
    Study site
    AdventHealth Neuroscience Institute
    Registry record
    NCT05877885 · updated
  5. ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Study site
    Clinical Neuroscience Solutions, Inc.
    Registry record
    NCT07284667 · updated
  6. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    LivaNova
    Study sites
    APG Research, LLC · Nova Psychiatry Inc.
    Registry record
    NCT03887715 · updated
  7. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Charter Research - Orlando
    Registry record
    NCT07412756 · updated
  8. Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    APG Research LLC
    Registry record
    NCT06372964 · updated
  9. TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

    • Observational
    • From 18 months, up to 11 years
    • All sexes
    Sponsor
    State University of New York at Buffalo
    Study site
    Nemours Foundation
    Registry record
    NCT07048574 · updated
  10. A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Charter Research Orlando
    Registry record
    NCT07716098 · updated
  11. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Orlando, FL on ClinicalTrials.gov.

Schizophrenia studies recruiting in Orlando

  1. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  2. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    • Phase 3
    • Ages 13 to 17
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Apg Research, Llc
    Registry record
    NCT07288567 · updated
  3. A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Apg Research, Llc
    Registry record
    NCT07424404 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Orlando, FL on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Orlando

  1. A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Charter Research - Orlando
    Registry record
    NCT07286175 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Orlando, FL on ClinicalTrials.gov.

ADHD studies recruiting in Orlando

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated
  3. A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Alkermes, Inc.
    Study site
    Alkermes Investigational Site
    Registry record
    NCT07755410 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Orlando, FL on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Orlando

  1. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  2. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Orlando Health Cancer Institute ( Site 0012)
    Registry record
    NCT06841354 · updated
  3. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002)
    Registry record
    NCT06952504 · updated
  4. Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

    • Observational
    • Ages 50 to 85
    • All sexes
    Sponsor
    CND Life Sciences
    Study site
    Neurology One
    Registry record
    NCT07428447 · updated
  5. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study sites
    Advent Health Orlando · Charter Research - Winter Park/Orlando
    Registry record
    NCT07174310 · updated
  6. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Neurology One
    Registry record
    NCT06680830 · updated
  7. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    Neurology One (Site #205)
    Registry record
    NCT07432958 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Orlando, FL on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Orlando

  1. A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    Neurological Services of Orlando
    Registry record
    NCT07067463 · updated
  2. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Orlando, FL on ClinicalTrials.gov.

Epilepsy studies recruiting in Orlando

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Orlando Health Neuroscience Institute
    Registry record
    NCT05667142 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Orlando, FL on ClinicalTrials.gov.

Migraine studies recruiting in Orlando

  1. Study of EVO756 in Adults With Migraine

    • Phase 2
    • Ages 18 to 64
    • All sexes
    Sponsor
    Evommune, Inc.
    Study site
    Clinical Neuroscience Solutions, Inc.
    Registry record
    NCT07616128 · updated
  2. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Clinical Associates of Orlando, LLC
    Registry record
    NCT07816367 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Orlando, FL on ClinicalTrials.gov.

Ask about studies near Orlando

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call